SLC3A2 and central nervous system cancer: Moreover, diagnostic ROC analysis showcased the superior predictive accuracy of SLC3A2 in gliomas, evidenced by an Area Under the ROC Curve (AUC) of 0.974 (95% CI: 0.967–0.981), affirming its competency in differentiating glioma tissues from normal counterparts (Fig. 2E).